Hyphens Pharma International Limited Stock

Equities

1J5

SG1EE4000006

Pharmaceuticals

Market Closed - Singapore S.E. 04:44:51 2024-05-31 am EDT 5-day change 1st Jan Change
0.275 SGD -1.79% Intraday chart for Hyphens Pharma International Limited -3.51% -3.51%
Sales 2024 * 183M 135M Sales 2025 * 192M 142M Capitalization 84.94M 62.87M
Net income 2024 * 11M 8.14M Net income 2025 * 12M 8.88M EV / Sales 2024 * 0.46 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.44 x
P/E ratio 2024 *
7.65 x
P/E ratio 2025 *
7.08 x
Employees 431
Yield 2024 *
3.85%
Yield 2025 *
4.05%
Free-Float 18.12%
More Fundamentals * Assessed data
Dynamic Chart
Singapore Shares Drop in Red Despite Global Rally; Biolidics Surges 20% on Wider Losses in Q1 MT
Hyphens Pharma's Q1 Net Profit Nearly Doubles on Broad-Based Sales Growth; Stock Climbs 6% MT
Hyphens Pharma International Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023 CI
Hyphens Pharma International Limited's Equity Buyback announced on April 2, 2024, has expired. CI
Hyphens Pharma’s Attributable Profit Narrows in 2023 MT
Hyphens Pharma International Limited Proposes Final Tax Exempt (One-Tier) Dividend CI
Hyphens Pharma Buys Back Shares MT
Hyphens Pharma International Limited commences an Equity Buyback Plan for 30,877,620 shares, representing 10% of its issued share capital, under the authorization approved on April 26, 2023. CI
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.35 From SG$0.32, Keeps at Add MT
Hyphens Pharma Obtains License to MC2's Psoriasis Cream MT
Hyphens Pharma International Limited Signs Exclusive Distribution Agreement with Cooper Pharma, S.A CI
Hyphens Pharma International Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyphens Pharma Strikes Distribution Deal With 7-Eleven Singapore MT
Hyphens Pharma Partners 7-Eleven to Offer Ocean Health Supplements in Singapore CI
More news
1 day-1.79%
1 week-3.51%
3 months-1.79%
Current year-3.51%
More quotes
1 week
0.28
Extreme 0.275
0.29
1 month
0.26
Extreme 0.26
0.30
Current year
0.26
Extreme 0.26
0.31
1 year
0.26
Extreme 0.26
0.33
3 years
0.26
Extreme 0.26
0.38
5 years
0.18
Extreme 0.18
0.63
10 years
0.16
Extreme 0.16
0.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 97-12-31
Director of Finance/CFO - 22-12-31
Chief Operating Officer 59 19-08-31
Members of the board TitleAgeSince
Director/Board Member 59 18-04-22
Director/Board Member 52 20-11-04
Chief Executive Officer 56 97-12-31
More insiders
Date Price Change Volume
24-05-31 0.275 -1.79% 19,400
24-05-30 0.28 -1.75% 10,000
24-05-28 0.285 +1.79% 64,600
24-05-27 0.28 -1.75% 100,100
24-05-24 0.285 -.--% 20,500

Delayed Quote Singapore S.E., May 31, 2024 at 04:44 am EDT

More quotes
Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.275 SGD
Average target price
0.35 SGD
Spread / Average Target
+27.27%
Consensus

Annual profits - Rate of surprise